Novozymes A/S
NVZMY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -15.01 | -0.38 | 1.53 | 3.87 |
| FCF Yield | 0.58% | 2.03% | 1.14% | 1.87% |
| EV / EBITDA | 14.21 | 20.04 | 15.87 | 27.88 |
| Quality | ||||
| ROIC | 3.36% | 12.72% | 15.56% | 16.71% |
| Gross Margin | 47.20% | 54.32% | 54.56% | 57.68% |
| Cash Conversion Ratio | 3.34 | 1.37 | 1.09 | 1.29 |
| Growth | ||||
| Revenue 3-Year CAGR | -39.78% | 6.18% | 7.80% | 1.32% |
| Free Cash Flow Growth | -68.51% | 87.81% | -60.45% | -17.36% |
| Safety | ||||
| Net Debt / EBITDA | 0.19 | 1.21 | -0.10 | -0.09 |
| Interest Coverage | 8.63 | 171.11 | 45.38 | 39.28 |
| Efficiency | ||||
| Inventory Turnover | 2.81 | 2.25 | 2.09 | 2.11 |
| Cash Conversion Cycle | 130.26 | 100.85 | 99.71 | 98.15 |